The New Indian Corporate Balance Sheet : More Fundraising, More Risk?
BIZ MASALA | SIGNATURE STORY
By Murthy ASR | 13 October 2026
India Inc.
is raising record amounts of equity capital. But a fundraising headline is not
the same thing as a factory, a research lab, a new job—or a stronger balance
sheet.
The record is real. The interpretation needs care.
Indian companies raised ₹2.43 lakh crore
through public equity markets in April–September 2026, a record for the first
half of a financial year and 75% more than a year earlier, according to PRIME
Database figures reported by Reuters. The Nifty 50 rose only 1.3% over the same
period. The contrast is striking: companies found a deep pool of capital even
while the broader secondary market delivered a modest return.
That surge matters. Equity capital can fund
expansion without adding scheduled interest payments. It can repair leverage,
finance acquisitions, or give early investors a route to sell. But these uses
are not economically equivalent. The central question for investors, employees
and policymakers is not simply how much was raised. It is what the money was
meant to do, how much reached the company, and whether the results later
justify the price paid.
Selected components reported for H1 FY27;
amounts are not intended to be added as a complete reconciliation. Public
reporting and data classifications can differ.
The first distinction: fresh money versus money changing
hands
An IPO can contain a fresh issue, in which
the company receives proceeds, and an offer for sale (OFS), in which existing
shareholders sell their shares. A QIP generally issues new shares and raises
money for the issuer, while a government divestment transfers ownership from
the state to public investors. All can be described as fundraising or market
mobilisation, but only some directly inject new capital into the business.
Reuters reported ₹2.43 lakh crore in total
public-equity fundraising for the half-year. A separate market summary based on
PRIME Database figures estimated that about ₹1.14 lakh crore—roughly 47%—was
fresh capital for companies, with the balance largely attributable to selling
shareholders. The exact composition should be checked against the underlying
PRIME Database tables before publication; the key point is conceptual as much
as numerical: headline proceeds can overstate the money available for corporate
investment.
Source: H1 FY27 public reporting of PRIME
Database figures. The fresh-capital figure is a reported estimate; verify
against the original dataset before republication.
Four destinations for a rupee of capital
1. Capacity, technology and research
This is the most straightforward growth
case: a manufacturer builds a plant, a power company expands generation, a
technology business invests in product development, or a healthcare company
adds clinical and diagnostic capacity. The benefits may appear slowly, but the
evidence eventually becomes tangible—capital expenditure, commissioning, higher
capacity utilisation, sales, productivity and jobs. Investors should look for a
timeline, not just a promise.
2. Debt repayment and refinancing
Repaying borrowings can be prudent. Lower
interest expense and a longer maturity profile may reduce the probability of
distress, free cash flow and allow management to invest later. But refinancing
is not the same as new productive investment. A company that repeatedly raises
capital to meet old obligations needs a clear explanation of why operating cash
flows have not become sufficient—and whether the new funding merely postpones
the problem.
3. Acquisitions and expansion by purchase
Acquisitions can deliver technology,
distribution, customers or scale faster than building from scratch. They can
also create integration costs, goodwill, additional borrowing and pressure to
deliver synergies. The test is whether the acquisition earns an adequate return
on the full purchase price, including financing and integration costs. Deal
announcements are not proof of value creation; post-deal cash flows are.
4. Promoter and investor exits
An offer for sale can broaden ownership,
improve liquidity and give early investors a legitimate exit after years of
risk-taking. It is not inherently a negative signal. Yet it should not be
presented as fresh investment into the company. The prospectus should make the
split between fresh issue and OFS unmistakable, and investors should ask why
selling shareholders are exiting now, how much they retain, and whether
governance aligns with minority shareholders after listing.
What the current pipeline tells us—and what it does not
The fundraising wave is not limited to one
kind of issuer. Reuters reported major offerings during the half-year,
including the National Stock Exchange, SBI Funds Management and Manipal Health
Enterprises, alongside a rise in qualified institutional placements and
government stake sales. On 12 October, Reuters reported that Zetwerk’s proposed
IPO combined a fresh issue intended partly for debt repayment and inorganic
growth with a much larger offer for sale by founders and investors. That
structure is a useful case study in why every issue needs to be read line by
line: the same transaction can simultaneously fund the company and provide
liquidity to existing holders.
The examples do not establish that the
market is overvalued, nor that companies are misusing capital. They show why
aggregate fundraising totals are an incomplete measure of corporate health. The
answer lies in company-level disclosures and subsequent performance.
The balance-sheet test: five questions every investor
should ask
1.
How much is a fresh issue, and
how much is an offer for sale?
2.
What specific uses of proceeds
are promised, and are they measurable?
3.
If proceeds repay debt, what
are net debt, interest coverage and the next major maturities?
4.
If proceeds fund acquisitions,
what return-on-capital target and integration milestones will management
disclose?
5.
Within 12–24 months, what
evidence will show that the money created cash flow, capacity, productivity or
sustainable earnings?
This is a reporting framework, not a rating
of any named company.
The risk is not fundraising. It is weak accountability
after fundraising.
Equity is generally more loss-absorbing
than debt: shareholders do not have a contractual coupon to collect, and a
well-priced equity issue can strengthen a company. The risks are different,
however. Existing shareholders may be diluted; new investors may overpay;
proceeds may sit idle; acquisitions may underperform; or management may miss
the promised milestones. For debt-funded deals, leverage and refinancing risk
add another layer.
Nor should every promoter sale be treated
as an alarm bell. Founders and early investors may diversify after years of
concentrated risk. The relevant questions are the scale and timing of the sale,
the use of any fresh proceeds, post-issue ownership, related-party transactions
and whether insiders remain exposed to the company's long-term outcome.
What would change the verdict?
The next phase of this story should follow
the money after the transaction closes. For each major issuer, compare the
prospectus or placement document with annual reports and quarterly filings:
promised capital expenditure versus actual spending; debt repayment versus net
debt; acquisition price versus cash generated; and announced hiring or capacity
versus delivered outcomes. Where disclosures are vague, that is itself a
governance question—not proof of wrongdoing.
For Telangana and Andhra Pradesh, the local
reporting opportunity is to identify listed and unlisted firms raising capital
for manufacturing, data centres, pharma, logistics, infrastructure and
industrial parks, then check what has actually been built, commissioned and
staffed. Announced investment, approved investment, money raised and completed
investment should be tracked as separate stages.
The bottom line
India's
capital markets are demonstrating depth. Whether that depth becomes economic
value depends on capital allocation and accountability.
A record fundraising season is a measure of
investor appetite and companies’ access to markets. It is not, by itself, a
measure of productive investment or future returns. The true scorecard will be
written later—in cash flows, lower leverage where promised, productive
capacity, competitive businesses and jobs. Until then, investors should
celebrate the availability of capital, but interrogate what each rupee is
expected to achieve.
Sources and editorial notes
·
Reuters, 12 October 2026 — Zetwerk IPO: fresh issue,
offer for sale and planned use of proceeds
·
SEBI, February 2026 Bulletin — capital raising and market
participation context
·
Economic Times, H1 FY27 IPO fundraising summary
Editorial caveat: fundraising totals vary
by instrument and definition. IPO proceeds can include both fresh issues and
offers for sale; public equity totals can include QIPs and government
divestments. The chart components are selected reported categories and should
not be treated as a complete additive reconciliation. This story distinguishes
reported facts from analytical questions and does not allege misuse of funds by
any company.
Biz Masala Masala
Business. Markets. People. Insight.
By Murthy ASR
Comments
Post a Comment